Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
funding
Biotech
F2G, Shionogi prep regulatory push after antifungal passes ph. 3
F2G and Shionogi have released phase 3 data for olorofim demonstrating its non-inferiority compared with an existing drug for invasive aspergillosis.
Will Maddox
Jun 18, 2026 12:01am
Vedana surfaces with $46M to develop migraine prevention therapies
Jun 17, 2026 9:48am
Blackstone Invests $250M in Anagram to reduce CF pill burden
May 7, 2026 10:36am
Private Swiss biotechs hit record funding in 2025
May 4, 2026 10:00pm
Ray shines a light on $125M round targeting genetic eye therapy
Apr 21, 2026 10:33am
Storm secures $56M series C, launches ph. 2 sarcoma trial
Apr 16, 2026 10:12am
